Contributions
Abstract: EP1442
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Background: Since 2013, an association between gadolinium based contrast agents (GBCAs) administration and increased signal intensity (SI) in the dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images has been reported. In particular, linear chelate type GBCAs have been described to cause these abnormalities, while the role of macrocyclic chelate type GBCAs is still debated.
Objectives: To compare the SI of dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images after repeated administrations of macrocyclic chelate type GBCAs to the baseline values in multiple sclerosis (MS) patients.
Methods and patients: We compared SI ratios (dentate nucleus-to-pons and globus pallidus-to-thalamus) after at least 3 administrations of macrocyclic chelate type GBCAs (gadobutrol, gadoteridol, and gadoterate meglumine) to baseline values, obtained on the same 1.5 T MRI scanner. Moreover, we also considered renal and liver function changes, when available.
Results: 24 MS patients have been enrolled (18 females, 6 males; mean age 47,6±11,6 years). All patients underwent at least 3 GBCA administrations (median 5, range 3-8). The average total doses of gadobutrol, gadoteridol, and gadoterate meglumine were 33,5±11,7 ml, 17,1±7,5 ml, and 13,5±4,9 ml, respectively, with a median dose-to-dose interval of 17 months (range 2-65 months). At the end of the study, we did not find any change in dentate nucleus-to-pons and globus pallidus-to-thalamus SI ratios compared to baseline (p=0,67 and p=0,43, respectively). Similarly, renal and liver functions remained normal and stable, with a slight reduction of bilirubin levels.
Discussion and conclusions: In our small single-center study, we confirm the previously described absence of effect of repeated administration of macrocyclic chelate type GBCAs on SI of the dentate nucleus and globus pallidus. Our data, despite the limited number of enrolled patients, support the safety of the macrocyclic chelate type GBCAs.
Disclosure:
Arianna Sartori: nothing to disclose
Antonio Giulio Gennari: nothing to disclose
Irene Zorzenon: nothing to disclose
Alessio Bratina: nothing to disclose
Maja Ukmar: nothing to disclose
Antonio Bosco: nothing to disclose
Lucia Tesolin: nothing to disclose
Maria Elisa Morelli: nothing to disclose
Alessandro Dinoto: nothing to disclose
Maria Assunta Cova: nothing to disclose
Paolo Manganotti: nothing to disclose
Abstract: EP1442
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Background: Since 2013, an association between gadolinium based contrast agents (GBCAs) administration and increased signal intensity (SI) in the dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images has been reported. In particular, linear chelate type GBCAs have been described to cause these abnormalities, while the role of macrocyclic chelate type GBCAs is still debated.
Objectives: To compare the SI of dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images after repeated administrations of macrocyclic chelate type GBCAs to the baseline values in multiple sclerosis (MS) patients.
Methods and patients: We compared SI ratios (dentate nucleus-to-pons and globus pallidus-to-thalamus) after at least 3 administrations of macrocyclic chelate type GBCAs (gadobutrol, gadoteridol, and gadoterate meglumine) to baseline values, obtained on the same 1.5 T MRI scanner. Moreover, we also considered renal and liver function changes, when available.
Results: 24 MS patients have been enrolled (18 females, 6 males; mean age 47,6±11,6 years). All patients underwent at least 3 GBCA administrations (median 5, range 3-8). The average total doses of gadobutrol, gadoteridol, and gadoterate meglumine were 33,5±11,7 ml, 17,1±7,5 ml, and 13,5±4,9 ml, respectively, with a median dose-to-dose interval of 17 months (range 2-65 months). At the end of the study, we did not find any change in dentate nucleus-to-pons and globus pallidus-to-thalamus SI ratios compared to baseline (p=0,67 and p=0,43, respectively). Similarly, renal and liver functions remained normal and stable, with a slight reduction of bilirubin levels.
Discussion and conclusions: In our small single-center study, we confirm the previously described absence of effect of repeated administration of macrocyclic chelate type GBCAs on SI of the dentate nucleus and globus pallidus. Our data, despite the limited number of enrolled patients, support the safety of the macrocyclic chelate type GBCAs.
Disclosure:
Arianna Sartori: nothing to disclose
Antonio Giulio Gennari: nothing to disclose
Irene Zorzenon: nothing to disclose
Alessio Bratina: nothing to disclose
Maja Ukmar: nothing to disclose
Antonio Bosco: nothing to disclose
Lucia Tesolin: nothing to disclose
Maria Elisa Morelli: nothing to disclose
Alessandro Dinoto: nothing to disclose
Maria Assunta Cova: nothing to disclose
Paolo Manganotti: nothing to disclose